体重指数与转移性黑色素瘤系统治疗结局的相关性:MelBase 法国队列数据分析
基于法国 MelBase 多中心前瞻性队列的回顾性分析纳入 1214 例不可切除 III/IV 期黑色素瘤成人患者,评估 BMI 与系统治疗生存结局及不良事件的关系。中位随访 13.5 个月,合并分析未观察到 BMI 与无进展生存(P=0.88)或总生存(P=0.25)相关,且不受治疗类型、性别和年龄影响;客观缓解率和治疗相关不良事件在不同 BMI 分类间亦无显著差异。结论提示 BMI 不是转移性黑色素瘤系统治疗结局的有价值标志物。
要点
- BMI 与转移性黑色素瘤系统治疗的无进展生存和总生存均无显著关联。
- BMI 与客观缓解率及治疗相关不良事件亦无显著关联。
- 未来研究可关注全身身体成分分布而非单一 BMI 指标。
核心结论
- BMI 与转移性黑色素瘤系统治疗生存结局无关,不是有价值的疗效标志物。
研究设计与样本
- 多中心回顾性研究,数据来自法国 MelBase 前瞻性队列(NCT02828202),2013 年 3 月 1 日至 2019 年 4 月 29 日入组。
- 纳入 1214 例不可切除 III 期或 IV 期黑色素瘤成人患者,接受一线化疗、靶向治疗或免疫治疗。
- 排除体重过低者及黏膜或眼部黑色素瘤转移患者,BMI 按世界卫生组织标准分类。
主要发现
- 中位年龄 66.0 岁(范围 53-75),男性 738 例(61%),免疫检查点抑制剂治疗占 63%,靶向治疗占 32%,M1c 期占 60.5%,肥胖患者占 22%。
- 中位随访 13.5 个月(范围 6.0-27.5),合并分析中 BMI 与无进展生存(P=0.88)和总生存(P=0.25)均无关联,且不受治疗类型、性别和年龄影响。
- 单因素和多因素分析结果均无统计学显著性,不同 BMI 分类的客观缓解率无显著差异,治疗相关不良事件与 BMI 无关。
临床怎么用
- 临床不应将 BMI 作为转移性黑色素瘤系统治疗疗效或不良事件的预测指标。
- 未来可探索全身身体成分分布等替代指标来评估治疗结局。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 仅纳入接受一线系统治疗的患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 'obesity paradox' suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor therapy. Higher BMI is also associated with higher incidences of treatment-related adverse events (TRAEs). This study assesses whether BMI is associated with survival outcomes and adverse events in metastatic melanoma patients with systemic therapy. PATIENTS AND METHODS: This multicentric retrospective study, conducted from 1 March 2013 to 29 April 2019, enrolled adults with unresectable stage III or IV melanoma from the French multicentric prospective cohort-MelBase (NCT02828202). Patients with first-line chemotherapy and targeted and immune therapy were included. Underweight people and those with metastatic mucosal or ocular melanoma were excluded. BMI was categorized using the World Health Organization criteria. Co-primary outcomes included the association between BMI and progression-free survival and overall survival, stratified by treatment type, sex, and age. Secondary endpoints were the association of BMI with overall response and TRAEs. Multivariate analyses were carried out. RESULTS: A total of 1214 patients were analyzed. Their median age was 66.0 years (range, 53-75). Male predominance was observed [n = 738 (61%)]. Most patients received immune checkpoint inhibitor therapy (63%), followed by targeted therapy (32%), and had stage M1c disease (60.5%). Obese patients represented 22% of the cohort. The median follow-up duration was 13.5 months (range, 6.0-27.5). In the pooled analysis, no positive or negative association between BMI and progression-free survival (P = 0.88)/overall survival (P = 0.25) was observed, regardless of treatment type, sex, and age. These results were nonsignificant in the univariate and multivariate analyses. The objective response rate, according to BMI category, did not differ significantly regardless of age. TRAEs were not associated with BMI. CONCLUSION: The observed lack of an association between BMI and survival demonstrates that BMI is not a valuable marker of systemic treatment-related outcomes in metastatic melanoma. Future approaches might focus on the whole-body distribution.
引用
- Di Filippo Y, Dalle S, Mortier L, et al. Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆. Ann Oncol. 2020. PMID: 33385520. doi:10.1016/j.annonc.2020.12.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。